NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 9 December 2011 The AIM-HIGH study found that adding nicotinic acid to simvastatin▼* (with or without ezetimibe) to further intensify lipid-modification in people with stable cardiovascular (CV) disease had […]
Category Archives: Lipids
NPC Archive Item: SHARP RCT shows ezetimibe/simvastatin reduces CV events in CKD: but is it better than simvastatin alone?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 19 August 2011 The SHARP RCT of ezetimibe plus simvastatin▼* in patients with chronic kidney disease (CKD), which was previously reported in a Merck press release in 2010, has […]
NPC Archive Item: Cochrane review supports NICE guidance for statins in primary prevention
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 11th February 2011 Results from a Cochrane review supports previous evidence that statins reduce all-cause mortality, combined fatal and non-fatal endpoints (CHD, CV disease and stroke events) and revascularisation […]
NPC Archive Item: Limited observational evidence for CV risk reduction with exenatide▼
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 2 December 2010 A retrospective, US-based cohort study identified that patients with type 2 diabetes who were prescribed exenatide▼ twice daily were less likely to have a cardiovascular (CV) event […]
NPC Archive Item: Ezetimibe/simvastatin may reduce CV events in CKD: but is it better than simvastatin alone?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 2 December 2010 A press release from Merck reports the results of a study showing that ezetimibe/simvastatin (10/20mg daily) was more effective than placebo in reducing the risk of major […]
NPC Archive Item: SEARCH finds simvastatin▼ 80mg vs 20mg does not reduce vascular events
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 23 November 2010 The SEARCH study has been published in full. It found no significant reduction in major vascular events among people randomised to simvastatin▼* 80mg vs 20mg per […]
NPC Archive Item: Shifting views on lipid lowering therapy
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 23 August 2010 A review of lipid lowering therapy argues that lipid modification should focus on strategies that are known to improve patient-oriented outcomes (e.g. simvastatin▼* 40mg daily), rather than […]
NPC Archive Item: May Drug Safety Update from MHRA/CHM
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The Drug Safety Update is an NHS Evidence accredited provider 26 May 2010 The MHRA and CHM have published the May edition of Drug Safety Update This edition includes […]
NPC Archive Item: What is the place in therapy of simvastatin 80mg in the light of recent MHRA guidance?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 25 May 2010 The May edition of Drug Safety Update includes an article advising healthcare professionals that the product information for simvastatin has been updated to highlight the increased […]
NPC Archive Item: A key message on intensive blood-pressure control in type 2 diabetes mellitus from ACCORD
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 20 April 2010 The ACCORD blood-pressure (BP) study conducted in patients with type 2 diabetes at high risk for cardiovascular (CV) disease concluded that intensive BP control to a target […]